Before that expands our horizon, we need to adhere the conventional guidelines for management of arrhythmias and heart failure in these patients, and strictly limit our precision therapy with sodium channel blockers only as an alternative therapy to those with known gain-of-function SCN5A variants. This evidence concerns the gene SCN5A and cardiac arrhythmia.